Deals in Depth: January 2010
Executive Summary
Alliance dollars were low in January, with only three biopharma deals reaching a potential deal value of $100 million or more, led by Ipsen and Inspiration's collaboration in hemophilia, worth $518 million. The bigger M&A dollars were seen in the device and diagnostic sectors, including Medtronic's take-out of CV device firm Invatec and its affiliates for $500 million. Both biopharma and device financing were down compared with December.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.